MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$1.97 +2.02%

+$0.08 today

Market cap
$125.90M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.72M

Average 0.98M

MGNX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

MacroGenics, Inc.NASDAQ: MGNX

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 54.3% from a year ago

Cash & equivalents stood at $66.52M at the end of Q1 FY2026, down 54.3% from a year earlier and up 16.3% from the prior quarter. Over 3 fiscal years it compounded at -19.3% a year.

Context

  • Cash & equivalents amounted to 30.5% of total assets at the end of Q1 FY2026, down 34.3 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -54.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$66.52M+16.3% QoQ
Last fiscal yearDec 2025
$57.22M-68.7% YoY
Year agoMar 2025
$145.57M-54.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.3%——
1 year-68.7%——
3-year CAGR-19.3%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
57.22M USD
Year-over-year change
-68.7%
4-year CAGR
-17.5%

Cash & Equivalents vs competitors

How MGNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -54.3% is the 8th highest of 11, against a peer median of -39.3%.
  • Cash & equivalents amounts to 30.5% of total assets for MGNX, versus a peer median of 36.2%.
MGNX Competitors
Cash & Equivalents for MGNX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OVIDOvid Therapeutics Inc.Mar 2026$94.06M USD+345.0%-33.6%41.7%
STTKShattuck Labs, Inc.Mar 2026$90.42M USD+48.5%+4.6%88.5%
MGNXMacroGenics, Inc.Mar 2026$66.52M USD-54.3%-19.3%30.5%
CNTXContext Therapeutics Inc.Mar 2026$54.53M USD-39.0%+23.0%92.6%
COYACoya Therapeutics, Inc.Mar 2026$50.72M USD+42.8%+99.1%95.2%
CNTBConnect Biopharma Holdings LimitedDec 2025$38.35M USD-51.0%-21.4%68.4%
WHWKWhitehawk Therapeutics IncMar 2026$34.79M USD-84.7%-1.3%27.3%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$31.93M USD-23.8%-5.8%12.6%
IFRXInflaRx N.V.Mar 2026€15.01M EUR-68.3%-0.5%30.7%
ORMPOramed Pharmaceuticals Inc.Mar 2026$13.2M USD-82.3%+4.3%4.9%
CLNNClene Inc.Mar 2026$5.94M USD-39.6%-34.3%27.4%
Peer median (excluding MGNX) —-39.3%-0.9%36.2%

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents123.47M108.88M100.96M182.84M57.22M
Short-term Investments120.15M45.46M128.85M18.83M132.7M
Net Receivables10.39M56.22M10.37M4.31M13.37M
Inventory4.39M1.45M1.22M07.91M
Other Current Assets010.16M9.95M11.51M8.75M
Total Current Assets279.56M222.18M251.34M217.49M219.94M
Property, Plant & Equipment (Net)54.29M56.91M45.69M42.61M35.52M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets09.04M000
Other Non-current Assets1.4M1.38M1.39M10.46M1.39M
Total Non-current Assets55.69M67.33M47.08M53.07M36.91M
Total Assets335.25M289.51M298.42M261.66M256.85M
Account Payables15.5M4.9M6.44M5.01M4.79M
Short-term Debt04.73M005.18M
Tax Payables00000
Deferred Revenue09.99M21.65M16.32M10.92M
Other Current Liabilities20.65M29M0022.23M
Total Current Liabilities74.58M48.61M56.11M55.53M43.12M
Long-term Debt000070M
Deferred Tax Liabilities09.04M08.9M0
Deferred Revenue (Non-current)059.48M59.24M55.5M55.5M
Other Non-current Liabilities258K258K258K1.97M1.05M
Total Non-current Liabilities21.05M98.89M89.7M98.97M158.14M
Total Liabilities95.63M147.5M145.81M145.6M201.26M
Common Stock613K617K621K628K633K
Retained Earnings(973.94M)(1.09B)(1.1B)(1.17B)(1.24B)
Accumulated OCI(61K)(5K)(6K)4K32K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity239.62M142.01M152.61M116.06M55.59M
Total Debt25.47M34.83M33.97M37.46M106.76M
Net Debt(98M)(74.05M)(66.99M)(145.38M)49.55M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$1.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.